Home Authors Posts by Winway Health Desk

Winway Health Desk

4038 POSTS 0 COMMENTS

FDA Approves Osphena (ospemifene) for Moderate to Severe Vaginal Dryness Due...

BLAINVILLE, QC, January 29, 2019 – Duchesnay Inc., a pharmaceutical company specializing in women’s health, announced today that the FDA has approved its supplemental...

Dr. David Nash: “No outcome, no income” should be basis for...

There are plenty of colleges offering medical degrees, nursing degrees and physician assistant degrees. But a degree in population health? That’s rare. Yet it’s...

Test run of drug prices in ads exposes a loophole—and pharma’s...

It’s no surprise that listing the high price of a drug in advertising would discourage consumers. But add in an offer to help cover the...

MedCity News to bring ENGAGE patient engagement conference to HLTH

Patient engagement has been a core coverage area for MedCity News and our commitment to the topic was solidified when we launched our ENGAGE...

Ready for Botox, millennials? Allergan has launched its first campaign targeting...

Allergan’s latest target for Botox Cosmetic is millennials. If there's any doubt, just look at the crowd of 20-somethings in its newly launched TV...

Livongo moves into behavioral health with acquisition of Denver-based myStrength

Mountain View, California-based chronic disease management company Livongo Health has made a major play in behavioral health with the purchase of Denver, Colorado-based myStrength...

Republicans and Democrats unite with Trump on pledge to lower drug...

Some Wall Street analysts who cover Big Pharma have been warning investors for months that if politicians on both sides of the aisle join...

Advocate Aurora Health and Oak Street Health will open primary care...

Advocate Aurora Health, a nonprofit system with hospitals and care sites in Illinois and Wisconsin, has teamed up with Oak Street Health to open...

Pfizer’s Xtandi blows by Johnson & Johnson’s Erleada with hot start...

You may not see it in sales numbers yet, but Pfizer and Astellas’ Xtandi is crushing Johnson & Johnson’s Erleada in the nonmetastatic, castration-resistant...

Polaris Partners launches Dewpoint Therapeutics with $60M round

A venture capital firm is starting a new company that will investigate potential drugs that target what it calls an unexplored area of cell...
0FansLike
65,684FollowersFollow
25,017SubscribersSubscribe

EDITOR PICKS